PHILADELPHIA — Nearly 10 percent of patients who are prescribed opioid medications following heart surgery will continue to use opioids more than 90 days after the procedure, according to a new study led by researchers in the Perelman School of Medicine at the University of Pennsylvania.
The study, published today in JAMA Cardiology, also revealed a direct link between the dosage of opioids—or oral morphine equivalent (OME)—first prescribed following discharge and the likelihood of persistent opioid use 90 to 180 days after the procedure. Patients who were prescribed more than 300mg OMEs (about 40 tablets of 5mg oxycodone) had a significantly higher risk of prolonged use compared to those who received a lower dosage.
“Our findings support a much-needed shift toward decreasing opioid dosages at discharge and using alternative approaches to reduce the risk for persistent opioid use,” said the study’s lead author Chase Brown, MD, MHSP, a Cardiovascular Surgery resident and research fellow.
Opioids, such as oxycodone, codeine, tramadol and morphine, are routinely prescribed for postoperative pain management in many countries. However, recent research suggests that overprescribing opioid medications for short-term pain may be widespread in the United States. The excessive prescribing can increase the risk of drug diversion, new long-term opioid use and the development of opioid use disorder.
Heart disease is the leading cause of death in the United States, accounting for about one in every four deaths. Every year, hundreds of thousands of people undergo heart surgery to treat conditions of the heart. While recent studies revealed that persistent opioid use occurs in 3 to 10 percent of patients after minor and major general surgery procedures, there is limited large-scale research that examines this issue among cardiac surgery patients in the United States.
In this study, the Penn team sought to determine the proportion of opioid-naïve patients who develop persistent opioid use after heart surgery and to investigate the link between the dosage first prescribed and the patient’s risk of prolonged use. Using a national database, the team examined data of 25,673 patients who underwent coronary artery bypass grafting—the most common type of heart surgery—or heart valve repair or replacement between 2004 and 2016.
More than half of the patients—about 60 percent of CABG patients and 53 percent of valve surgery patients—filled an opioid prescription within 14 days of the surgery. Researchers found that 9.6 percent of the cardiac surgery patients continued to fill prescriptions between three and six months after surgery, with the refill rate slightly higher among CABG patients. In fact, nearly 9 percent of CABG patients continued to fill an opioid prescription 180 to 270 days after surgery. The team also found a higher incidence rate among women, younger patients and those with preexisting medical conditions, such as congestive heart failure, chronic lung disease, diabetes and kidney failure.
To examine whether the results would apply to patients considered “low risk,” researchers excluded patients who had preoperative use of benzodiazepines, muscle relaxants, alcoholism, chronic pain, drug use and those discharged to a facility after cardiac surgery. Researchers found a similar incidence rate among the low-risk cohort, with 8 percent of the patients continuing to use opioids between 90 and 180 days of their discharge.
“Cardiothoracic surgeons, cardiologists and primary care physicians should work together to enact evidence-based protocols to identify high-risk patients and minimize prescriptions via a multi-faceted pain management approach,” said the study’s senior author Nimesh Desai, MD, PhD, a cardiovascular surgeon and an associate professor of Surgery. “Centers must adopt protocols to increase patient education and limit opioid prescriptions at discharge.”
Additional Penn authors include Zehang Chen, Fabliha Khurshan, and Peter W. Groeneveld.
The research was supported, in part, by the National Research Service Award postdoctoral fellowship (T32HL007843).
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.